文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

90Y-FAPI-46放射性配体治疗晚期实体瘤的初步临床经验:9例病例系列

Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients.
PubMed 文献 · J Nucl Med · 2021-08-12

该病例系列纳入9例经多学科肿瘤委员会决定已无获批治疗方案的晚期实体瘤患者(软组织或骨肉瘤6例,胰腺癌3例),且要求FAP高表达(SUVmax≥10的病灶超过50%)。90Y-FAPI-46治疗耐受性良好,归因不良事件发生率低;7/9例(78%)治疗后韧致辐射显像显示肿瘤摄取充足;4例(50%)达到影像学疾病控制;肾脏平均吸收剂量0.52 Gy/GBq,骨髓0.04 Gy/GBq。

要点

  • 90Y-FAPI-46治疗耐受性良好,无归因于治疗的急性毒性。
  • 7/9例(78%)治疗后韧致辐射显像显示肿瘤病灶摄取充足。
  • 4例(50%)达到影像学疾病控制,但疗效需更大样本验证。

核心结论

  • FAP靶向的90Y-FAPI-46放射性配体治疗耐受性良好,归因不良事件发生率低。
  • 关键器官辐射剂量较低,提示重复周期治疗可行。
  • 观察到肿瘤缓解迹象,但疗效与毒性特征需更大队列进一步研究。

研究设计与样本

  • 单中心病例系列,纳入9例经多学科肿瘤委员会决定已无获批治疗方案的晚期实体瘤患者。
  • 入组要求FAP高表达,定义为SUVmax≥10的病灶占所有病灶的50%以上。
  • 治疗时间为2020年6月至2021年1月。

主要发现

  • 9例患者中转移性软组织或骨肉瘤6例,胰腺癌3例。
  • 首周期中位给药活度3.8 GBq(IQR 3.25-5.40 GBq),3例接受后续周期,中位7.4 GBq(IQR 7.3-7.5 GBq)。
  • 治疗后90Y-FAPI-46韧致辐射显像显示7/9例(78%)肿瘤病灶摄取充足。
  • 新发G3或G4实验室毒性4例(44%),其中2例仅血小板减少,2例新发血小板减少合并贫血。
  • 影像学疾病控制4例(50%)。

关键数值与推荐

  • 入组FAP高表达标准:SUVmax≥10的病灶占所有病灶的50%以上。
  • 肾脏平均吸收剂量0.52 Gy/GBq(IQR 0.41-0.65 Gy/GBq)。
  • 骨髓平均吸收剂量0.04 Gy/GBq(IQR 0.03-0.06 Gy/GBq)。
  • 肺和肝平均吸收剂量低于0.26 Gy/GBq。
  • 测量肿瘤病灶吸收剂量最高达2.28 Gy/GBq(中位1.28 Gy/GBq)。

临床怎么用

  • 对于已无获批治疗方案的FAP高表达晚期实体瘤患者,90Y-FAPI-46可作为探索性治疗选择。
  • 治疗前后应进行90Y-FAPI-46韧致辐射显像和PET扫描以确认分布与剂量。
  • 需监测血液学毒性,尤其是血小板减少和贫血。

局限性

  • 样本量小(9例),为初步病例系列。
  • 疗效与毒性特征需更大队列进一步研究确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibroblast activation protein (FAP) is overexpressed in several solid tumors and therefore represents an attractive target for radiotheranostic applications. Recent investigations demonstrated rapid and high uptake of small-molecule inhibitors of FAP (68Ga-FAPI-46) for PET imaging. Here, we report our initial experience of the feasibility and safety of 90Y-FAPI-46 for radioligand therapy of extensively pretreated patients with solid tumors. Methods: Patients were considered for 90Y-FAPI-46 therapy if they showed both an exhaustion of all approved therapies based on multidisciplinary tumor board decision, and high FAP expression, defined as SUVmax greater than or equal to 10 in more than 50% of all lesions. If tolerated, 90Y-FAPI-46 bremsstrahlung scintigraphy was performed after therapy to confirm systemic distribution and focal tumor uptake, and 90Y-FAPI-46 PET scans were performed at multiple time points to determine absorbed dose. Blood-based dosimetry was used to determine bone marrow absorbed dose. Adverse events were graded using Common Terminology Criteria for Adverse Events (version 5.0). Results: Nine patients either with metastatic soft-tissue or bone sarcoma (n = 6) or with pancreatic cancer (n = 3) were treated between June 2020 and March 2021. Patients received a median of 3.8 GBq (interquartile range [IQR], 3.25-5.40 GBq) for the first cycle, and 3 patients received subsequent cycles with a median of 7.4 GBq (IQR, 7.3-7.5 GBq). Posttreatment 90Y-FAPI-46 bremsstrahlung scintigraphy demonstrated sufficient 90Y-FAPI-46 uptake in tumor lesions in 7 of 9 patients (78%). Mean absorbed dose was 0.52 Gy/GBq (IQR, 0.41-0.65 Gy/GBq) in the kidney, 0.04 Gy/GBq (IQR, 0.03-0.06 Gy/GBq) in bone marrow, and less than 0.26 Gy/GBq in the lung and liver. Measured tumor lesions received up to 2.28 Gy/GBq (median, 1.28 Gy/GBq). New laboratory G3 or G4 toxicities were noted in 4 patients (44%, n = 2 patients with thrombocytopenia only, n = 2 patients with new onset of thrombocytopenia and anemia). Other G3 or G4 laboratory-based adverse events occurred in 2 patients or fewer. No acute toxicities attributed to 90Y-FAPI-46 were noted. Radiographic disease control was noted in 4 patients (50%). Conclusion: FAP-targeted radioligand therapy with 90Y-FAPI-46 was well tolerated, with a low rate of attributable adverse events. Low radiation doses to at-risk organs suggest feasibility of repeat cycles of 90Y-FAPI-46. We observed signs of tumor response, but further studies are warranted to determine efficacy and the toxicity profile in a larger cohort.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ferdinandus J, Costa PF, Kessler L, et al. Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients. J Nucl Med. 2021. PMID: 34385340. doi:10.2967/jnumed.121.262468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。